header-langage
简体中文
繁體中文
English
Tiếng Việt
한국어
日本語
ภาษาไทย
Türkçe
Scan to Download the APP
Partnered With:

Cancer Begins to Be "Programmed": AI Targets, mRNA Made on the Spot, Phase III Succeeds

Dynamic Insight: Beating AI News Flash: The personalized cancer therapy, intismeran, developed jointly by mRNA drug development company Moderna and Merck, has yielded positive results in Phase III clinical trials. After 1137 high-risk melanoma patients underwent surgery, using intismeran in combination with Keytruda, compared to Keytruda alone, both the recurrence and distant metastasis, the two main endpoints, showed significant improvement. Detailed efficacy data has not yet been released.

What sets this drug apart is that each patient receives a unique formulation. Physicians first sequence the patient's tumor and blood to identify unique mutations in the cancer cells. Moderna then uses a set of AI algorithms to analyze these mutations, predicting up to 34 of the most likely "neoantigens" that could trigger an immune response—essentially identifying cancer cell targets suitable for immune system attack.

After selecting the targets, Moderna encodes them into a segment of mRNA tailor-made for that specific patient. Once injected into the body, the mRNA instructs cells to produce these cancer-specific features, training the immune system to recognize and attack cancer cells with the same features. Since each person's tumor mutations are different and the AI-selected targets vary, the resulting mRNA is also unique to each patient.

In the past, cancer drugs were typically developed first and then administered to a cohort of eligible patients. Intismeran reverses this process: it reads a person's cancer, transforms the tumor into sequencing data, computes targets, and then encodes the results into a drug. The success of this Phase III trial indicates that this "one drug per person" approach can now be successfully implemented in large-scale clinical trials.

举报 Correction/Report
RelatedRecommended
Clinical Breakthrough Real, but Surge Detached from Fundamentals
Major Cloud Provider Leveraging Capital Tool to Enhance Supply Chain Resilience
A quick overview of Compound III in conversation with Jared Flatow, Vice President of Engineering at Compound Labs.
Correction/Report
Submit
Add Library
Visible to myself only
Public
Save
Choose Library
Add Library
Cancel
Finish